Rayner is best known for its intraocular lenses (IOLs). It developed the world’s first IOL and is the sole manufacturer of IOLs in the UK. The company currently manufactures 1.3 million lenses a year, but there’s more to the story. Rayner’s portfolio also includes a delivery system, ophthalmic viscosurgical devices, drops, and a digital health platform that captures  patient-reported outcomes.CEO Tim Clover discusses Rayner’s diversified focus and data-driven initiatives with OIS Podcast host Sophia Pathai, MD, PhD. They also talk about how Clover helped move the company in a new direction, which included tearing down one factory and moving into a new R&D, training, and production facility in Worthing, West Sussex, England.Clover also helped Rayner secure a partnership with Brussels-based HASA OPTIX, which manufactures single-use ophthalmic surgical instruments.Listen to the podcast to discover: The challenges of Clover’s transition from a nonexecutive director role to CEO, both individually and for the organization.What’s new with Rayner and how it plans to acquire real-world data from its lenses.Rayner’s new Peer2Peer initiative to engage with leading, high-volume, and emerging key opinion leaders (KOLs).Clover’s thoughts on nurturing the next generation of industry leaders.The gaps in the eye care device industry and how professionals can come together to affect change.What motivates Clover every day as a leader. Hint: It has little to do with innovation. Click “play” to listen.